Logo image of REVB

REVELATION BIOSCIENCES INC (REVB) Stock Fundamental Analysis

NASDAQ:REVB - Nasdaq - US76135L6065 - Common Stock - Currency: USD

2.44  -0.05 (-2.01%)

After market: 2.5989 +0.16 (+6.51%)

Fundamental Rating

2

REVB gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 553 industry peers in the Biotechnology industry. REVB scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. REVB is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

REVB had negative earnings in the past year.
In the past year REVB has reported a negative cash flow from operations.
In the past 5 years REVB always reported negative net income.
REVB had a negative operating cash flow in each of the past 5 years.
REVB Yearly Net Income VS EBIT VS OCF VS FCFREVB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -5M -10M -15M

1.2 Ratios

REVB has a worse Return On Assets (-362.90%) than 94.21% of its industry peers.
Looking at the Return On Equity, with a value of -500.15%, REVB is doing worse than 77.58% of the companies in the same industry.
Industry RankSector Rank
ROA -362.9%
ROE -500.15%
ROIC N/A
ROA(3y)-141.62%
ROA(5y)-213.33%
ROE(3y)-450.21%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
REVB Yearly ROA, ROE, ROICREVB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 2K 4K 6K 8K 10K

1.3 Margins

REVB does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
REVB Yearly Profit, Operating, Gross MarginsREVB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

6

2. Health

2.1 Basic Checks

Compared to 1 year ago, REVB has more shares outstanding
REVB has less shares outstanding than it did 5 years ago.
There is no outstanding debt for REVB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
REVB Yearly Shares OutstandingREVB Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 5M 10M 15M
REVB Yearly Total Debt VS Total AssetsREVB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

2.2 Solvency

Based on the Altman-Z score of -18.88, we must say that REVB is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of REVB (-18.88) is worse than 83.91% of its industry peers.
There is no outstanding debt for REVB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -18.88
ROIC/WACCN/A
WACCN/A
REVB Yearly LT Debt VS Equity VS FCFREVB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 5M -5M -10M -15M

2.3 Liquidity

A Current Ratio of 3.61 indicates that REVB has no problem at all paying its short term obligations.
With a Current ratio value of 3.61, REVB perfoms like the industry average, outperforming 41.77% of the companies in the same industry.
A Quick Ratio of 3.61 indicates that REVB has no problem at all paying its short term obligations.
With a Quick ratio value of 3.61, REVB perfoms like the industry average, outperforming 43.58% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.61
Quick Ratio 3.61
REVB Yearly Current Assets VS Current LiabilitesREVB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 76.37% over the past year.
EPS 1Y (TTM)76.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%83.92%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

REVB is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.02% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y90.34%
EPS Next 2Y40.01%
EPS Next 3Y25.19%
EPS Next 5Y15.02%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
REVB Yearly Revenue VS EstimatesREVB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 2031 50M 100M 150M
REVB Yearly EPS VS EstimatesREVB Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 -10K -20K -30K -40K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for REVB. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for REVB. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
REVB Price Earnings VS Forward Price EarningsREVB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
REVB Per share dataREVB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -20 -40 -60 -80 -100

4.3 Compensation for Growth

REVB's earnings are expected to grow with 25.19% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.01%
EPS Next 3Y25.19%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for REVB!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

REVELATION BIOSCIENCES INC

NASDAQ:REVB (8/1/2025, 8:00:02 PM)

After market: 2.5989 +0.16 (+6.51%)

2.44

-0.05 (-2.01%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-08 2025-05-08/amc
Earnings (Next)08-07 2025-08-07/bmo
Inst Owners2.08%
Inst Owner Change0%
Ins Owners2.79%
Ins Owner Change1.56%
Market Cap3.73M
Analysts82.86
Price Target522.42 (21310.66%)
Short Float %N/A
Short Ratio0.15
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)40.09%
Min EPS beat(2)10.25%
Max EPS beat(2)69.93%
EPS beat(4)3
Avg EPS beat(4)-6.86%
Min EPS beat(4)-178.64%
Max EPS beat(4)71%
EPS beat(8)6
Avg EPS beat(8)8.74%
EPS beat(12)10
Avg EPS beat(12)53.52%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)200%
PT rev (3m)200%
EPS NQ rev (1m)-200%
EPS NQ rev (3m)25.31%
EPS NY rev (1m)-125.32%
EPS NY rev (3m)34.6%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.3
P/tB 1.3
EV/EBITDA N/A
EPS(TTM)-116.79
EYN/A
EPS(NY)-5.94
Fwd EYN/A
FCF(TTM)-11.95
FCFYN/A
OCF(TTM)-11.95
OCFYN/A
SpS0
BVpS1.88
TBVpS1.88
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -362.9%
ROE -500.15%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-141.62%
ROA(5y)-213.33%
ROE(3y)-450.21%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.61
Quick Ratio 3.61
Altman-Z -18.88
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)76.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%83.92%
EPS Next Y90.34%
EPS Next 2Y40.01%
EPS Next 3Y25.19%
EPS Next 5Y15.02%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y8.62%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-129.49%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-129.49%
OCF growth 3YN/A
OCF growth 5YN/A